Clinical update of medications associated with QT prolongation among COVID-19 patients

Authors : Ernest Herbert, Dominique Fournier

Pages : 732-741

Doi:10.18621/eurj.1102545

View : 16 | Download : 15

Publication Date : 2022-09-04

Article Type : Other

Abstract :In the struggle against COVID-19 pandemic, chloroquine (CQ) (a 4-aminoquinoline) and its derivative hydroxychloroquine (HCQ) have both been used as a potential form of treatment among infected patients. Originally known as an antimalarial quinolone, many countries have adopted their use as an option to treat COVID-19 patients. In humans, dose-dependent chloroquine induces QT interval prolongation. It also blocks the human ether-a-go-go-related gene (hERG), which encodes the rapidly activating delayed rectifier K+ channel. The action potential duration is then prolonged, as the eventual QTc interval of the electrocardiogram (ECG), resulting in torsade de pointes and cardiac arrhythmias that could lead to sudden death. It is yet unknown whether COVID-19 itself has any effect on the QTc interval. The current review established what is new and different from other studies involving the use of chloroquine and hydroxychloroquine among COVID-19 patients plus the corresponding QT interval prolongation in affected individuals.
Keywords : Long QT prolongation, hERG, ionic channels, drug repurposing, mobile devices, SARS-CoV-2